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Abstract Guidelines for the management of osteoporosis
induced by endogenous hypercortisolism are not available.
Both the American College of Rheumatology and the Inter-
national Osteoporosis Foundation recommend to modulate
the treatment of exogenous glucocorticoid-induced osteopo-
rosis (GIO) based on the individual fracture risk profile (cal-
culated by FRAX) and dose of glucocorticoid used, but it is
difficult to translate corticosteroid dosages to different degrees
of endogenous hypercortisolism, and there are no data on
validation of FRAX stratification method in patients with
endogenous hypercortisolism. Consequently, it is unclear
whether such recommendations may be adapted to patients
with endogenous hypercortisolism. Moreover, patients with
exogenous GIO take glucocorticoids since suffering a disease
that commonly affects bone. On the other hand, the correction
of coexistent risk factors, which may contribute to increase the
fracture risk in patients exposed to glucocorticoid excess, and
the removal of the cause of endogenous hypercortisolism,
may lead to the recovery of bone health. Although the correc-
tion of hypercortisolism and of possible coexistent risk factors
is necessary to favor the normalization of bone turnover with
recovery of bone mass; in some patients, the fracture risk
could not be normalized and specific anti-osteoporotic drugs
should be given. Who, when, and how the patient with
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endogenous hypercortisolism should be treated with bone-
active therapy is discussed.
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Introduction
Glucocorticoid-induced osteoporosis (GIO) is the most com-
mon form of secondary osteoporosis [1]. Although the ad-
verse skeletal effects of glucocorticoids have been recognized
for decades, attention to GIO has increased recently because
of the widespread clinical use of glucocorticoids in a variety of
disorders including autoimmune, pulmonary, and gastrointes-
tinal diseases, malignancies, and in patients receiving organ
transplants [1]. As in GIO caused by glucocorticoid treatment,
skeletal fragility is a frequent complication of endogenous
hypercortisolism, which is caused by pituitary adenoma (i.e.,
Cushing’s disease), adrenal adenoma, or hyperplasia (i.e.,
ACTH-independent Cushing’s syndrome) or neoplasia with
unexpected ACTH secretion (i.e., ectopic ACTH-dependent
Cushing’s syndrome) [2, 3].
Pathophysiology
Exogenous and endogenous Cushing’s syndrome (CS) shares
common pathophysiological and clinical aspects, as far as
skeletal fragility is concerned [4]. In both the conditions, the
impairment of osteoblast differentiation and function is among
the pathophysiological mechanisms leading to bone loss and
increase in fracture risk [4]. Glucocorticoids may also affect
the number and function of osteocytes, inducing apoptosis,
and reducing mineral matrix with an increase in lacunar size
[5, 6]. These effects of glucocorticoids on osteoblasts and
osteocytes might account for a disproportionate loss of bone
strength in relation to bone mass. In fact, in both endogenous
and exogenous hypercortisolism, fractures may develop even
in the presence of normal or low-normal bone mineral density
(BMD), as measured by DXA [7]. In both the clinical condi-
tions, fractures occur predominantly at the vertebral site [1,
8–10], with potential clinical implications in frail patients as
are those exposed to glucocorticoid excess [11, 12]. Despite
these common skeletal features, there are peculiar biological
and clinical aspects that make difficult the clinical and thera-
peutic management of skeletal fragility in patients with en-
dogenous CS. It is beyond the aim of the current perspective to
give information on diagnostic criteria, classification, and
epidemiology of CS, and for details we suggest the “Endo-
crine Society Clinical Practice Guideline” [13].
Applying the general concept that removing the underlying
disease may resolve secondary osteoporosis, it should be
expected that treatment of endogenous hypercortisolism may
lead to the recovery of bone health [14, 15], an opportunity
that cannot be commonly realized in patients with exogenous
GIO in whom glucocorticoids are taken for therapeutic pur-
poses. However, the intuitive concept of recovery of bone
health after correction of glucocorticoid excess in endogenous
hypercortisolism could not always occur in the clinical prac-
tice for different reasons. Firstly, the correction of
hypercortisolismwhen caused by a pituitary disease or ectopic
ACTH secretion may take a long time implying a multistep
therapeutic approach [16], while vertebral fractures tend to
occur early during the natural history of disease. In fact,
incident vertebral fractures were observed in about one half
of patients with hypercortisolism followed for 1 year [17]. On
the other hand, the resolution of endogenous hypercortisolism
is not always accompanied by a complete recovery of bone
loss, and fracture risk may persist high in some patients with
cured disease [18].
Treatment of coexistent risk factors
The above considerations imply that a skeletal-specific ap-
proach should be taken into account in patients with endoge-
nous hypercortisolism, regardless of the correction of hormon-
al disorder. A first step could be the identification and possible
correction of coexistent risk factors which may contribute to
increase the fracture risk in patients exposed to glucocorticoid
excess [4]. The correction of hypovitaminosis D and the
negative calcium balance associated with hypercortisolism is
an intuitive approach to reduce fracture risk in patients with
GIO and all patients exposed to glucocorticoid excess should
be treated with adequate supplementation of vitamin D and
calcium [19, 20]. This approach seems to be particularly
important to reduce the fracture risk in patients with endoge-
nous hypercortisolism in whom adequate amounts of vitamin
D and calcium are likely required to support the rapid miner-
alization of the newly formed bone matrix occurring after the
removal of cause of glucocorticoid excess [21, 22].
Hypogonadism frequently occurs in patients with CS and
contributes to bone loss and increased risk of fragility fractures
[2, 4, 23, 24]. Although in animal models, sex steroids were
shown to protect skeletal from deleterious effects of glucocor-
ticoids excess [25], there are no data on the anti-fracture
effects of sex steroid replacement therapy in humans with
endogenous hypercortisolism.Moreover, estrogen administra-
tion in patients with endogenous hypercortisolism may poten-
tially worsen the pro-thrombotic effects of these drugs [19]. A
functional growth hormone (GH) deficiency has been de-
scribed in patients exposed to glucocorticoid excess [2], and
this condition may itself cause osteoporosis and fractures [26,
27]. The final pathways of bone damage are similar for both
glucocorticoid excess and GH deficiency [2, 26] and the
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coexistence of two disorders may increase the risk of fractures
[28]. In patients with CS, impairment of GH secretion could
be persistent long after correction of hypercortisolism and the
time of normalization of GH reserve was shown to be variable
in the different experiences ranging from 6 months to more
than 3 years after treatment of hypercortisolism [29–31].
Theoretically, a window of opportunity may exist for GH
treatment in patients with glucocorticoid-induced osteoporosis
[32], such as proposed for children with persistent GH defi-
ciency after treatment of Cushing’s disease in whom GH
treatment may favor the “catch-up” growth and ensure the
achievement of final height [33]. However, despite the poten-
tial beneficial effects of recombinant GH treatment, there are
still important concerns about the potential drawbacks of such
a therapy in patients chronically exposed to glucocorticoid
excess. Both recombinant GH and glucocorticoid treatment
are known to induce insulin resistance in hepatic and periph-
eral tissues, and potentially to result in glucose intolerance
[34, 35].
Evaluation of fracture risk and bone-active therapy
Besides the correction of coexistent risk factors for fractures,
anti-osteoporotic drugs may be needed in some patients in
whom fractures risk could not be normalized by correction of
hypercortisolism. Indeed, the identification of patients in
whom an anti-osteoporotic treatment should be performed
may be a clinical challenge. In fact, the literature data on this
issue are scanty and there are no available guidelines for the
management of osteoporosis induced by endogenous
hypercortisolism. Both the American College of Rheumatol-
ogy and the International Osteoporosis Foundation recom-
mend modulating the treatment of exogenous GIO based on
the individual fracture risk profile (calculated by FRAX) and
dose of glucocorticoid used [19, 20]. It is unclear whether
such recommendations may be adopted to patients with en-
dogenous hypercortisolism, since it is difficult to translate
corticosteroid dosages to different degrees of endogenous
hypercortisolism; moreover, in GIO, glucocorticoids are taken
for therapeutic purposes, commonly for the treatment of dis-
eases that per se affect bone, and finally, there are no data on
validation of FRAX stratification method in patients with
endogenous hypercortisolism. Taking into account these lim-
itations, some concepts of the current guidelines of GIO could
be applied to patients with endogenous hypercortisolism pro-
posing a bone active treatment for post-menopausal women or
men older than 50 years with a 10-year risk for fractures of at
least 20 %, as calculated by FRAX, or in patients older than
70, and/or with BMD < −1.5 SD, and/or prevalent fractures,
and/or with more severe hypercortisolism (e.g., ectopic Cush-
ing syndrome) (Fig. 1). Young patients (premenopausal wom-
en or men aged less than 50 years) in the absence of fractures
are considered at low risk factor and should be treated with
calcium and vitamin D in particular if hypercortisolism is
rapidly corrected by surgery. Moreover, anti-osteoporotic
drugs should be reserved to patients with long-term
hypercortisolism, even subclinical, not adequately corrected
by specific treatments. The ideal drug to be used in this
specific clinical context should be the one able to counteract
the negative skeletal effects of glucocorticoids and to favor the
recovery of bone remodeling after resolution of endogenous
hypercortisolism. On the first point, there is convincing evi-
dence that both bisphosphonates and teriparatide are effective
in counteracting the negative effects of glucocorticoids on
bone [19, 20], whereas it is still unknown whether and how
anti-osteoporotic drugs may influence the recovery of bone
health after correction of endogenous hypercortisolism [14,
22]. Alendronate and clodronate were tested in patients with
endogenous hypercortisolism demonstrating positive effects
on BMD [36, 37]. However, data on fractures are lacking in
CS, and it is still unclear whether bisphosphonates are safe in
this clinical context. Differently, from patients exposed to
exogenous glucocorticoid excess, in endogenous
hypercortisolism, the early and transient phase of high bone
turnover (in this phase, there is a rationale for using such
drugs) is usually not identified since the disease is often
diagnosed late in respect of the biological appearance of
hypercortisolism. When endogenous CS is diagnosed, the
skeletal phenotype is usually characterized by a low bone
turnover osteoporosis with only slight and uncoupled increase
in bone resorption, as it classically occurs during chronic
treatment with glucocorticoids [38]. In this condition,
bisphosphonates may further suppress bone turnover, raising
clinical concern for rare undesired effects, as atypical
subtrochanteric fractures and osteonecrosis of the jaw, which
may be favored by glucocorticoid excess [39]. Moreover,
bisphosphonates have long-term antiresorptive effects, which
may affect the recovery of bone remodeling after correction of
hypercortisolism. Based on these pathophysiological and clin-
ical considerations, in our point of view, other antiresorptive
drugs could be preferred to bisphosphonates for treating pa-
tients with skeletal fragility by endogenous hypercortisolism,
which is expected to be corrected by surgery or medical
therapies. Denosumab, a monoclonal antibody against
RANK-ligand with rapid and transient antiresorptive effects
[40], was shown to be able to revert the skeletal effects of
glucocorticoids [41] and it could be an attractive drug (partic-
ularly for its on-off effects on bone) to be used for a short-term
treatment in patients with skeletal fragility induced by endog-
enous hypercortisolism which is expected to be cured. Since
the impairment of bone formation is the main pathophysio-
logical mechanism leading to bone loss in GIO [2],
teriparatide could be considered the best drug to treat skeletal
fragility in patients exposed to glucocorticoid excess either
exogenous [39] or endogenous [42]. However, there are still
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scanty data on the effectiveness and safety of teriparatide in
patients with endogenous hypercortisolism, in whom the out-
come of underlying neoplasia may be negatively influenced
by the use of this drug [43]. Data on animal models suggest
the potential utility of treatment with strontium ranelate in
glucocorticoid-induced osteoporosis [44]. However, prospec-
tive studies that evaluated the efficacy of strontium ranelate in
patients with glucocorticoid-induced osteoporosis have not
been published so far.
As above reported, in GIO or CS, the skeletal picture is
characterized by a low bone turnover osteoporosis with only
slight and uncoupled increase in bone resorption; consequent-
ly, bone turnover markers apart from their biological and
analytical variability cannot be utilized for making a decision
on treatment. On the other hand, serum osteocalcin is consid-
ered a sensitive biologic marker of glucocorticoid activity and
perhaps disease severity in CS. Indeed, osteocalcin levels are
suppressed in the presence of active disease but increase
rapidly (days) and remain stably high for months after the
cure of CS [45].
Adrenal or pituitary diseases could influence the therapeutic
approach; indeed, in adrenal CS, the disease is always cured,
whereas the prevalence of cure is lower in pituitary disease.
Consequently, the therapeutic approach should be more con-
servative in adrenal disease (vitamin D and calcium, and rapid
correction of hypercortisolism by surgery); while in pituitary
disease, the pharmacological approach for the prevention/
treatment of bone damage could be more aggressive.
A third matter of uncertainty is the timing of bone-active
therapy in patients with endogenous hypercortisolism. The
fracture risk stratification, as above proposed, and the thera-
peutic decision-making for hypercortisolism may help the
clinician in deciding if, when, and how to treat skeletal fragility
in patients with endogenous CS. In patients with baseline low
risk for fractures and in whom endogenous hypercortisolism is
expected to be rapidly corrected by surgery, anti-osteoporotic
drugs likely are not needed. Indeed, calcium and vitamin D
should be given to these patients, as well as in those at high-
fracture risk, for guaranteeing the catch up of bone mass and
quality with the recovery of bone remodeling after resolution
of hypercortisolism [20]. In patients with high-fracture risk
profile, however, anti-osteoporotic drugs in addition to calcium
and vitamin D should be started early before correction of
hypercortisolism. In this specific clinical context, the clinician
should use drugs, such as teriparatide, which may have the
double advantage to counteract the negative skeletal effects of
glucocorticoid excess and to favor the recovery of bone re-
modeling after the resolution of hypercortisolism. After the
correction of hypercortisolism, it is still unknownwhether anti-
osteoporotic drugs should be continued or withdrawn. After
some months from the resolution of the hypercortisolism, the
redefinition of fracture risk, based on FRAX profile and even-
tually BMD outcome, may help the clinician to decide whether
or not to continue the anti-osteoporotic drugs, such as proposed
for patients with exogenous GIO, taking into account that a
spontaneous recovery of bone mass may occur after correction
of glucocorticoid excess [38].
Conclusions
Skeletal fragility is a frequent complication of endogenous
hypercortisolism occurring early during the natural history of
disease. The correction of hypercortisolism is necessary to
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favor the normalization of bone turnover with recovery of
bone mass, but in some patients the fracture risk could not
be normalized and specific anti-osteoporotic drugs should be
given. The critical clinical questions are: Who should be
treated with anti-osteoporotic drugs? When to start treatment?
How should patients be treated? Indeed, the treatment of
skeletal fragility in patients with endogenous Cushing’s syn-
drome may be a clinical challenge because there are no
specific guidelines for this disease and data of literature do
not allow performing an evidence-based approach, but a
single-case evaluation is often needed. Vitamin D and calcium
should be always administered in all patients with endogenous
hypercortisolism, while in this specific clinical context other
studies are needed to clarify role, effectiveness, and safety of
antiresorptive and anabolic drugs.
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